• Users Online: 1078
  • Home
  • Print this page
  • Email this page

    Article Cited by others

REVIEW ARTICLE

Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli

Iacobino Angelo, Piccaro Giovanni, Giannoni Federico, Mustazzolu Alessandro, Fattorini Lanfranco

Year : 2017| Volume: 6| Issue : 3 | Page no: 213-221

   This article has been cited by
 
1 Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues
Styliani Xiroudaki,Federica Ianni,Samuele Sabbatini,Elena Roselletti,Claudia Monari,Roccaldo Sardella,Anna Vecchiarelli,Stefano Giovagnoli
Pharmaceutics. 2021; 13(1): 85
[Pubmed]  [Google Scholar] [DOI]
2 Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes
Qiang Su,Wei Kuang,Weiyi Hao,Jing Liang,Liang Wu,Chunmei Tang,Yali Wang,Tao Liu,Young-Su Yi
Mediators of Inflammation. 2021; 2021: 1
[Pubmed]  [Google Scholar] [DOI]
3 Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
Shashikant Srivastava,Kayle N. Cirrincione,Devyani Deshpande,Tawanda Gumbo
Frontiers in Pharmacology. 2021; 11
[Pubmed]  [Google Scholar] [DOI]
4 Molecule Property Analyses of Active Compounds for Mycobacterium Tuberculosis
Vadim Makarov,Elena Salina,Robert C. Reynolds,Phyo Phyo Kyaw Zin,Sean Ekins
Journal of Medicinal Chemistry. 2020;
[Pubmed]  [Google Scholar] [DOI]
5 Effects of Cigarette Smoke Condensate on Growth and Biofilm Formation by Mycobacterium tuberculosis
Moloko C. Cholo,Sipho S. M. Rasehlo,Eudri Venter,Chantelle Venter,Ronald Anderson
BioMed Research International. 2020; 2020: 1
[Pubmed]  [Google Scholar] [DOI]
6 Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In Vitro
E. D. Pieterman,M. J. Sarink,C. Sala,S. T. Cole,J. E. M. de Steenwinkel,H. I. Bax
Antimicrobial Agents and Chemotherapy. 2020; 64(7)
[Pubmed]  [Google Scholar] [DOI]
7 Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds
André Campaniço,Shrika G. Harjivan,Digby F. Warner,Rui Moreira,Francisca Lopes
International Journal of Molecular Sciences. 2020; 21(22): 8854
[Pubmed]  [Google Scholar] [DOI]
8 Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus
Jin Lee,Nicole Ammerman,Anusha Agarwal,Maram Naji,Si-Yang Li,Eric Nuermberger
Antimicrobial Agents and Chemotherapy. 2020; 65(2)
[Pubmed]  [Google Scholar] [DOI]
9 Drug-Resistant Tuberculosis 2020: Where We Stand
Angelo Iacobino,Lanfranco Fattorini,Federico Giannoni
Applied Sciences. 2020; 10(6): 2153
[Pubmed]  [Google Scholar] [DOI]
10 Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors
Bryan J. Berube,Dara Russell,Lina Castro,Seoung-ryoung Choi,Prabagaran Narayanasamy,Tanya Parish
Antimicrobial Agents and Chemotherapy. 2019; 63(6)
[Pubmed]  [Google Scholar] [DOI]
11 Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures
Yana R. Batyrshina,Yakov Sh Schwartz
Tuberculosis. 2019; 117: 7
[Pubmed]  [Google Scholar] [DOI]
12 Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence
Saif Khan,Raju K. Mandal,Abdulbaset Mohamed Elasbali,Sajad A. Dar,Arshad Jawed,Mohd Wahid,Harishankar Mahto,Mohtashim Lohani,Bhartendu Nath Mishra,Naseem Akhter,Ali A. Rabaan,Shafiul Haque
Bioscience Reports. 2019; 39(1)
[Pubmed]  [Google Scholar] [DOI]
13 A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis
Julie V. Early,Steven Mullen,Tanya Parish,Adelaide Almeida
PLOS ONE. 2019; 14(10): e0222970
[Pubmed]  [Google Scholar] [DOI]
14 Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients
Michael A. Lyons
Antimicrobial Agents and Chemotherapy. 2019; 63(12)
[Pubmed]  [Google Scholar] [DOI]
15 The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH
Angelo Iacobino,Federico Giannoni,Manuela Pardini,Giovanni Piccaro,Lanfranco Fattorini
Antimicrobial Agents and Chemotherapy. 2019; 63(7)
[Pubmed]  [Google Scholar] [DOI]
16 Development and biological evaluation of a new nanotheranostic for tuberculosis
Edward Helal-Neto,Suyene Rocha Pinto,Filipe Leal Portilho,Marcellus Dias da Costa,Jonathas Xavier Pereira,Fiammetta Nigro,Eduardo Ricci-Junior,Andre Luis Peixoto Candéa,Maria das Graças Muller de Oliveira Henri,Ralph Santos-Oliveira
Drug Delivery and Translational Research. 2018;
[Pubmed]  [Google Scholar] [DOI]
17 Activity of DNA-targeted C8-linked pyrrolobenzodiazepine–heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions
Angelo Iacobino,Federico Giannoni,Lanfranco Fattorini,Federico Brucoli
The Journal of Antibiotics. 2018;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article